Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CTSS | P25774 | 13/20 | 0.52 |
| ▸ | CTSK | P43235 | 11/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484195 | 1.00 | KMT2A (0.59) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL21125740 | 0.84 | KMT2A (0.47) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL8536880 | 0.82 | KMT2A (0.57) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL10760962 | 0.82 | KMT2A (0.57) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL8536884 | 0.82 | KMT2A (0.57) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL31517881 | 0.81 | KMT2A (0.56) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL3010367 | 0.81 | KMT2A (0.56) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL2390418 | 0.81 | KMT2A (0.56) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL12712549 | 0.81 | CTSS (0.74) | CTSSCTSKCTSLCTSB | |
| SCHEMBL18884395 | 0.81 | CTSS (0.74) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311850-B | Imidazolone compounds as human neutrophil elastase inhibitors | 奇斯药制品公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | disclosed |
| EP-3464268-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2020-03-11 | — | — | EP | disclosed |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| US-10023558-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-07-17 | — | — | US | disclosed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023558-B2 | Compounds | SERPINB1, ELANE, MPO | KMT2A 3935/4885CTSS 118/4885CTSK 138/4885 |
| US-20170340611-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | KMT2A 4327/4885CTSS 214/4885CTSK 101/4885 |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | SERPINB1, ELANE, EPX | KMT2A 4207/4885CTSS 157/4885CTSK 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.